These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 24074240

  • 1. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
    Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M.
    BMC Psychiatry; 2013 Sep 27; 13():237. PubMed ID: 24074240
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
    Katzman MA, Sternat T.
    CNS Drugs; 2014 Nov 27; 28(11):1005-33. PubMed ID: 25120227
    [Abstract] [Full Text] [Related]

  • 4. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.
    Pediatrics; 2001 Jun 27; 107(6):E105. PubMed ID: 11389303
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov 27; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 7. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.
    Pediatrics; 2001 Oct 27; 108(4):883-92. PubMed ID: 11581440
    [Abstract] [Full Text] [Related]

  • 8. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P, Kodesh A, Weizman A.
    Clin Neuropharmacol; 2017 Oct 27; 40(1):11-15. PubMed ID: 27879551
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.
    van der Schans J, Kotsopoulos N, Hoekstra PJ, Hak E, Postma MJ.
    PLoS One; 2015 Oct 27; 10(5):e0127237. PubMed ID: 26024479
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.
    Curr Med Res Opin; 2011 Oct 27; 27 Suppl 2():35-44. PubMed ID: 21787126
    [Abstract] [Full Text] [Related]

  • 13. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.
    Döpfner M, Breuer D, Walter D, Rothenberger A.
    Eur Child Adolesc Psychiatry; 2011 Oct 27; 20 Suppl 2(Suppl 2):S277-88. PubMed ID: 21901414
    [Abstract] [Full Text] [Related]

  • 14. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
    Gormez V, Avery B, Mann H.
    Eur Rev Med Pharmacol Sci; 2013 Sep 27; 17(17):2345-9. PubMed ID: 24065228
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
    Maldonado R.
    Expert Opin Drug Metab Toxicol; 2013 Aug 27; 9(8):1001-14. PubMed ID: 23611637
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB, Gupta S, Heverin E, Starr HL.
    J Child Adolesc Psychopharmacol; 2011 Jun 27; 21(3):255-63. PubMed ID: 21663428
    [Abstract] [Full Text] [Related]

  • 18. The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.
    Zelnik N, Terkel-Dawer R.
    Atten Defic Hyperact Disord; 2015 Dec 27; 7(4):313-8. PubMed ID: 25838111
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.
    J Child Adolesc Psychopharmacol; 2011 Apr 27; 21(2):121-31. PubMed ID: 21488750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.